A Glimpse Into The Expert Outlook On Recursion Pharmaceuticals Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed reviews on Recursion Pharmaceuticals (NASDAQ:RXRX) over the past three months, with 3 bullish and 1 indifferent rating. The average 12-month price target is $13.75, down from $14.00, with a high of $15.00 and a low of $10.00. Recent analyst actions include maintaining and lowering ratings and price targets. Recursion Pharmaceuticals is a clinical-stage biotech company with a strong market presence but faces challenges in revenue growth, ROE, ROA, and debt management.
January 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Recursion Pharmaceuticals has received mixed analyst ratings with a slight decrease in the average price target. The company's financial challenges may weigh on investor sentiment.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on RXRX's stock price. The financial challenges highlighted, such as negative revenue trends and below-average ROE and ROA, could be concerning to investors, but the maintained 'Buy' ratings from some analysts could offset negative sentiment.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100